Research study Program year 2025 Source: CMS Open Payments

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

ClinicalTrials.gov NCT03731260

Research payments

$15,164,179

1,367 payments

Through program year 2025, $15,164,179 in research payments was reported against A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy, across 1,367 payments.

Paid by (largest first): Blueprint Medicines Corporation; Sanofi US Services Inc.
ClinicalTrials.gov: NCT03731260

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,386,541	201
2024	Research	$1,201,058	169
2023	Research	$1,652,347	228
2022	Research	$3,536,383	227
2021	Research	$4,022,546	201
2020	Research	$3,365,305	341

Breakdown

Who paid Research payments · program years 2020–2025

Blueprint Medicines Corporation $14,551,951 1,274 payments
Sanofi US Services Inc. $612,228 93 payments

Who received the money Research payments · program years 2020–2025

Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $2,505,190 106 payments
Board Of Trustees Of The Leland Stanford Junior University Organisation paid for research $2,232,946 153 payments
Brigham And Womens Hospital Teaching hospital · MA $2,219,546 96 payments
U Of U Hospitals & Clinics Teaching hospital · UT $1,507,550 90 payments
The Trustees Of Columbia University In The City Of New York Organisation paid for research $909,919 67 payments
Mayo Clinic Organisation paid for research $730,651 54 payments
Duke University Organisation paid for research $483,060 57 payments
Dana Farber/Partners Cancer Care INC Organisation paid for research $460,375 72 payments
Ut Md Anderson Cancer Center Teaching hospital · TX $445,500 31 payments
Virginia Commonwealth University Organisation paid for research $383,745 29 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy”, Who Paid My Doc, citing CMS Open Payments, program year 2025. https://www.whopaidmydoc.com/research-studies/a-3-part-randomized-double-blind-placebo-controlled-phase-2-study-to-evaluate-safety-and-efficacy-of-avapritinib-blu-285-a-selective-kit-mutation-targeted-tyrosine-kinase-inhibitor-in-indolent-and-smoldering-systemic-mastocytosis-with-symptoms-inadequately-controlled-with-standard-therapy-60216697

Figures here may be reproduced with attribution and a link — see for journalists and researchers.